Skip to content
trifluoperazine

Structure via PubChem · Public domain (PubChem)

EntityQ1752915· pop 22· linked from 2,212 articles

trifluoperazine

Sign in to save

Also known as Eskazinyl®, Stelazine®, trifluoperazine hydrochloride, 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine, Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine, Trifluoperazinum, Trifluperazine, 10-[3-(4-METHYL-piperazin-1-yl)-propyl]-2-trifluoromethyl-10H-phenothiazine

Trifluoperazine, marketed under the brand name Stelazine among others, is a typical antipsychotic primarily used to treat schizophrenia. It may also be used short term in those with generalized anxiety disorder but is less preferred to benzodiazepines. It is of the phenothiazine chemical class. It was approved for medical use in the United States in 1959.

Chemical data

Formula
C21H24F3N3S
Molecular weight
407.5 g/mol
IUPAC name
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine
SMILES
CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
InChIKey
ZEWQUBUPAILYHI-UHFFFAOYSA-N
XLogP
5
Polar surface area
35 Ų
H-bond donors
0
H-bond acceptors
7
Formal charge
0

via PubChem

Research

5,313 papers

via PubMed

~4 min read

Encyclopedic overview

8 sections
Contents
  • Medical uses
  • Schizophrenia
  • Other
  • Side effects
  • Contraindications
  • Mechanism of action
  • Names
  • References

Trifluoperazine, marketed under the brand name Stelazine among others, is a typical antipsychotic primarily used to treat schizophrenia. It may also be used short term in those with generalized anxiety disorder but is less preferred to benzodiazepines. It is of the phenothiazine chemical class. It was approved for medical use in the United States in 1959.

== Medical uses == ===Schizophrenia=== Trifluoperazine is an effective antipsychotic for people with schizophrenia condition. There is low-quality evidence that trifluoperazine increases the chance of being improved when compared to placebo when people are followed up for 19 weeks. There is low-quality evidence that trifluoperazine reduces the risk of relapse when compared with placebo when people are followed for 5 months. As of 2014 there was no good evidence for a difference between trifluoperazine and placebo with respect to the risk of experiencing intensified symptoms over a 16-week period nor in reducing significant agitation or distress.

Excerpted from Wikipedia’s “trifluoperazine” article, available under the CC BY-SA 4.0 licence.